Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities

6 Months Ended

Jun. 30, 2020

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities

Note 9 — Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	June 30,		December 31,
	2020		2019
Accrued clinical and development expenditures	$	9,219	$	8,782
Accrued employee expenses		9,892		6,863
Other accrued expenditures		2,057		2,662
Accrued purchase commitments		2,500		5,000
Other		168		56
	$	23,836	$	23,363

In 2016, the Company entered into a supply agreement with ThermoFisher for the supply of the Dynabeads® CD3/CD28 technology. The supply agreement runs until December 31, 2025. Under the supply agreement, the Company is required to purchase its requirements for CD3/CD28 magnetic bead product exclusively from ThermoFisher for a period of 5 years. There are minimum purchasing obligations of $2.5 million due within the next year, which are included within accrued purchase commitments above.